Xin-Hui Pan
Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.
Pan, Xin-Hui; Tan, Bryan; Chin, Yip Han; Lee, Ethan Cheng Zhe; Kong, Gwyneth; Chong, Bryan; Kueh, Martin; Khoo, Chin Meng; Mehta, Anurag; Majety, Priyanka; Grandhi, Gowtham R; Dimitriadis, Georgios K; Foo, Roger; Chew, Nicholas W S; Le Roux, Carel W; Mamas, Mamas A; Chan, Mark Y
Authors
Bryan Tan
Yip Han Chin
Ethan Cheng Zhe Lee
Gwyneth Kong
Bryan Chong
Martin Kueh
Chin Meng Khoo
Anurag Mehta
Priyanka Majety
Gowtham R Grandhi
Georgios K Dimitriadis
Roger Foo
Nicholas W S Chew
Carel W Le Roux
Mamas Mamas m.mamas@keele.ac.uk
Mark Y Chan
Abstract
This network meta-analysis evaluates the efficacy and safety of tirzepatide compared to glucagon-like peptide-1 receptor agonists (GLP-1 RA) and other weight loss drugs in the treatment of overweight and obesity. MEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP-1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta-analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects. Thirty-one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight-related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42-16.34). As compared to placebo, tirzepatide and GLP-1 RA across all doses had significant increases in gastrointestinal adverse effects. The superiority of tirzepatide and GLP-1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity. [Abstract copyright: © 2024 The Obesity Society.]
Citation
Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., …Chan, M. Y. (in press). Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity, 32(5), 840-856. https://doi.org/10.1002/oby.24002
Journal Article Type | Review |
---|---|
Acceptance Date | Dec 27, 2023 |
Online Publication Date | Feb 27, 2024 |
Deposit Date | Mar 19, 2024 |
Journal | Obesity (Silver Spring, Md.) |
Print ISSN | 1930-7381 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 32 |
Issue | 5 |
Pages | 840-856 |
DOI | https://doi.org/10.1002/oby.24002 |
Public URL | https://keele-repository.worktribe.com/output/775806 |
You might also like
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search